MINDMAZE THERAPEUTICS HOLDING SA
MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland.
MINDMAZE THERAPEUTICS HOLDING SA (MMTX) - Net Assets
Latest net assets as of : CHF- CHF
Based on the latest financial reports, MINDMAZE THERAPEUTICS HOLDING SA (MMTX) has net assets worth CHF- CHF as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF-) and total liabilities (CHF-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MINDMAZE THERAPEUTICS HOLDING SA - Net Assets Trend (None–None)
This chart illustrates how MINDMAZE THERAPEUTICS HOLDING SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MINDMAZE THERAPEUTICS HOLDING SA (None–None)
The table below shows the annual net assets of MINDMAZE THERAPEUTICS HOLDING SA from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MINDMAZE THERAPEUTICS HOLDING SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MINDMAZE THERAPEUTICS HOLDING SA Competitors by Market Cap
The table below lists competitors of MINDMAZE THERAPEUTICS HOLDING SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AVICHINA IND -H- (AVT.SG)
STU:AVT
|
$4.38K |
|
Creativeforge Games SA
WAR:CFG
|
$4.39K |
|
JG Summit Holdings Inc
PSE:JGS
|
$4.39K |
|
Parx Plastics NV
PA:MLPRX
|
$4.39K |
|
Binh Thuan Books and Equipment JSC
VN:BST
|
$4.37K |
|
Linius Technologies Limited
PINK:LNNTF
|
$4.37K |
|
Systems Limited
KAR:SYS
|
$4.37K |
|
Stonepath Group Inc
PINK:SGRZ
|
$4.36K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MINDMAZE THERAPEUTICS HOLDING SA's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MINDMAZE THERAPEUTICS HOLDING SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MINDMAZE THERAPEUTICS HOLDING SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MINDMAZE THERAPEUTICS HOLDING SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $554,918,213
- Average return on equity (ROE) among peers: -212.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MINDMAZE THERAPEUTICS HOLDING SA (MMTX) | CHF- | N/A | N/A | $4.38K |
| BB Biotech AG (BION) | $1.91 Billion | 10.59% | 0.00x | $495.17K |
| Newron Pharmaceuticals SpA (NWRN) | $67.72 Million | -7.80% | 0.08x | $317.49 Million |
| Spexis AG (SPEX) | $2.29 Million | -857.53% | 6.33x | $4.21 Million |
| Xlife Sciences AG (XLS) | $235.23 Million | 6.08% | 1.08x | $70.33 Million |